TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07168993: Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence o

Sponsor: bioAffinity Technologies Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 2063 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07168993 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07168993 Rescue Dossier →